Effect of sirolimus as an immunosuppressive agent on kidney transplantation in patients with diabetes mellitus; a systematic review

Sirolimus is a macrolide and a type of immunosuppressant drug to prevent rejection
of transplanted organs. This drug inhibits the activation of T and B lymphocytes and reduces the
production of interleukin-2 (IL-2).
Objectives: This study aimed to review the effect of sirolimus in kidney transplantation in patients
with diabetes mellitus as a systematic review.
Materials and Methods: International databases including PubMed, Web of Science and Scopus were
considered for search of English articles by 29 June 2019. Twenty-one published articles were finally
entered into the study. Keywords were sirolimus, rapamune, rapamycin, diabetes mellitus and kidney
transplantation or a combination of them in the title/abstracts. Treatment using a combination of
sirolimus and tacrolimus were excluded.
Results: There were more than 3244 subjects reviewed in this systematic review including 21
published articles (Total population of 21 articles: 3244 people).
Conclusion: According to the results, sirolimus-based immunosuppression for preventing kidney
transplantation is effective and has a low-risk in diabetic patients resulting in suitable glucose control